Journal
SCIENCE TRANSLATIONAL MEDICINE
Volume 12, Issue 549, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.aaz6992
Keywords
-
Categories
Funding
- NIH TB Research Unit grant [U19 AI11143]
- Milstein Program in Chemical Biology and Translational Medicine
- Medical Scientist Training Program grant from the National Institute of General Medical Sciences under NIH [T32GM007739]
- National Institute of Allergy and Infectious Diseases under NIH [F30AI140623]
- National Defense Science and Engineering Graduate Fellowship from the U.S. Department of Defense
- Potts Memorial Foundation
- Department of Infectious Disease, Imperial College London
- MRC [MR/P028225/1] Funding Source: UKRI
Ask authors/readers for more resources
Insufficient development of new antibiotics and the rising resistance of bacteria to those that we have are putting the world at risk of losing the most widely curative class of medicines currently available. Preventing deaths from antimicrobial resistance (AMR) will require exploiting emerging knowledge not only about genetic AMR conferred by horizontal gene transfer or de novo mutations but also about phenotypic AMR, which lacks a stably heritable basis. This Review summarizes recent advances and continuing limitations in our understanding of AMR and suggests approaches for combating its clinical consequences, including identification of previously unexploited bacterial targets, new antimicrobial compounds, and improved combination drug regimens.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available